Logo image of NEUP

NEUPHORIA THERAPEUTICS INC (NEUP) Stock Fundamental Analysis

USA - NASDAQ:NEUP - US64136E1029 - Common Stock

13.01 USD
-0.98 (-7.01%)
Last: 9/12/2025, 8:01:39 PM
12.8 USD
-0.21 (-1.61%)
After Hours: 9/12/2025, 8:01:39 PM
Fundamental Rating

2

Overall NEUP gets a fundamental rating of 2 out of 10. We evaluated NEUP against 542 industry peers in the Biotechnology industry. NEUP may be in some trouble as it scores bad on both profitability and health. NEUP has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NEUP was profitable.
In the past 5 years NEUP always reported negative net income.
NEUP had a negative operating cash flow in each of the past 5 years.
NEUP Yearly Net Income VS EBIT VS OCF VS FCFNEUP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

NEUP's Return On Assets of -25.24% is fine compared to the rest of the industry. NEUP outperforms 72.51% of its industry peers.
NEUP has a better Return On Equity (-39.90%) than 71.77% of its industry peers.
Industry RankSector Rank
ROA -25.24%
ROE -39.9%
ROIC N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
NEUP Yearly ROA, ROE, ROICNEUP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

NEUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUP Yearly Profit, Operating, Gross MarginsNEUP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50K -100K

More info and screens

3

2. Health

2.1 Basic Checks

NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEUP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NEUP Yearly Shares OutstandingNEUP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M
NEUP Yearly Total Debt VS Total AssetsNEUP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

NEUP has an Altman-Z score of -8.17. This is a bad value and indicates that NEUP is not financially healthy and even has some risk of bankruptcy.
NEUP's Altman-Z score of -8.17 is on the low side compared to the rest of the industry. NEUP is outperformed by 68.45% of its industry peers.
NEUP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NEUP (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.17
ROIC/WACCN/A
WACC9.58%
NEUP Yearly LT Debt VS Equity VS FCFNEUP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

NEUP has a Current Ratio of 3.45. This indicates that NEUP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NEUP (3.45) is comparable to the rest of the industry.
A Quick Ratio of 3.45 indicates that NEUP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.45, NEUP is in line with its industry, outperforming 42.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
NEUP Yearly Current Assets VS Current LiabilitesNEUP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for NEUP have decreased strongly by -109.17% in the last year.
NEUP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.99%.
The Revenue for NEUP have been decreasing by -64.56% on average. This is quite bad
EPS 1Y (TTM)-109.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-86.99%
Revenue growth 3Y-9.79%
Revenue growth 5Y-64.56%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.89% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -18.92% on average over the next years. This is quite bad
EPS Next Y94.49%
EPS Next 2Y22.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-70.47%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NEUP Yearly Revenue VS EstimatesNEUP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M
NEUP Yearly EPS VS EstimatesNEUP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 2.50, the valuation of NEUP can be described as very cheap.
Based on the Price/Earnings ratio, NEUP is valued cheaper than 98.71% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.30, NEUP is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for NEUP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 2.5
Fwd PE N/A
NEUP Price Earnings VS Forward Price EarningsNEUP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUP Per share dataNEUP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NEUP's earnings are expected to grow with 22.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y22.89%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NEUP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUPHORIA THERAPEUTICS INC

NASDAQ:NEUP (9/12/2025, 8:01:39 PM)

After market: 12.8 -0.21 (-1.61%)

13.01

-0.98 (-7.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners8.14%
Inst Owner Change9.1%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap24.46M
Analysts82.86
Price Target46.58 (258.03%)
Short Float %0.63%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)117.46%
PT rev (3m)117.46%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.27%
Revenue NY rev (3m)2.27%
Valuation
Industry RankSector Rank
PE 2.5
Fwd PE N/A
P/S 1.56
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 7.34
EV/EBITDA N/A
EPS(TTM)5.21
EY40.05%
EPS(NY)-11.73
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.33
BVpS9.3
TBVpS1.77
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.24%
ROE -39.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -8.17
F-ScoreN/A
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-109.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y94.49%
EPS Next 2Y22.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-86.99%
Revenue growth 3Y-9.79%
Revenue growth 5Y-64.56%
Sales Q2Q%N/A
Revenue Next Year-70.47%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y-129.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.65%
OCF growth 3YN/A
OCF growth 5YN/A